Ligand Pharmaceuticals LGND EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's EBITDA margin?
- Ligand Pharmaceuticals (LGND) reported EBITDA margin of 46.6% in Q1 2026.
- How has Ligand Pharmaceuticals's EBITDA margin changed year-over-year?
- Ligand Pharmaceuticals's EBITDA margin increased by 418.1% year-over-year, from -14.6% to 46.6%.
- What is the long-term trend for Ligand Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's EBITDA margin has grown at a -3.8% compound annual growth rate (CAGR), from 33.9% to 27.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.